


PTO/SB/08A (10/01) (Substitute for form 1449A/PTO) 	ATTY. DOCKET NO. ARR003 Client/Matter No. 80248.0023.001	APPLICATION NO. 10/688,849
	FIRST NAMED INVENTOR Mark Munson	
	FILING DATE October 15, 2003	ART UNIT - 1644 1626

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)
Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document No. No. - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AF	1	5,945,418	08-31-1999	Bemis et al.	
	2	6,080,763	06-27-2000	Regan et al.	
	3	6,093,742	07-25-2000	Salituro et al.	
	4	6,214,830 B1	04-10-2001	Beers et al.	
	5	6,228,881	05-08-2001	Regan et al.	
	6	6,242,453	06-05-2001	Cirillo et al.	
	7	6,297,381	10-02-2001	Cirillo et al.	
	8	6,358,945 B1	03-19-2002	Breitfelder et al.	
	9	6,432,995 B2	08-13-2002	Hickey et al.	
	10	6,479,507 B2	11-12-2002	Cheng et al.	
	11	6,503,930 B1	01-07-2003	Hanson et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Doc cntry code - No. - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
AF	12	WO 97/12876	04-10-1997	Merck Co., Inc.		X	
	13	WO 00/71535 A1	11-30-2000	Scios Inc.		X	
	14	WO 01/02369 A2	01-11-2001	Agouron Pharmaceuticals, Inc.		X	
	15	WO 02/42292 A2	05-30-2002	Scios, Inc.		X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published

EXAMINER SIGNATURE /Andrew Freistein/ (08/01/2006)	DATE CONSIDERED 08/01/2006
---	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10/01) (Substitute for form 1449A/PTO)		ATTY. DOCKET NO. ARR003 Client/Matter No. 80248.0023.001		APPLICATION NO. 10/688,849		
<div style="position: relative; height: 100px;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 24px; font-weight: bold;"> O I P E FEB 06 2004 U.S. PATENT & TRADEMARK OFFICE </div> </div>		INFORMATION DISCLOSURE STATEMENT BY APPLICANT				
		FIRST NAMED INVENTOR Mark Munson				
(Use several sheets if necessary) Sheet 2 of 2		FILING DATE October 15, 2003		ART UNIT 1004 1626		
U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document No. No. - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Doc cntry code - No. - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	TRANSLATION YES NO
AF	16	WO 02/072579	09-19-2002	Pfizer Products, Inc		X
↓	17	WO 03/032989 A1	04-24-2003	Boehringer Ingelheim Pharmaceuticals		X
↓	18	WO 03/051847 A1	06-26-2003	Smithkline Beecham		X
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published				
AF	19	SALITURO, E.G., et al. "Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases," Current Medicinal Chemistry, 1999, 607-823.				
↓	20	FOSTER, M. L., et al., "Potential of p38 Inhibitors in the Treatment of Rheumatoid Arthritis," Drug News Perspect 13 (8), October 2000. pp 488-496.				
↓	21	BOEHM, J.D. and ADAMS, J. L. "Expert Opinion on Therapeutic Patents," 10:25-37 (2000).				
↓	22	NATARAJAN, SWAMINATHAN R., ET AL. "P38 MAP Kinase Inhibitors. Part 1: Design and Development of a New Class of Potent and Highly Selective Inhibitors Based on 3,4-Dihydropyrido, [3,2-d 1 Pyrimidone Scaffold," Bioorganic & Medicinal Chemistry Letters 13:273-276 (2003).				
EXAMINER SIGNATURE				DATE CONSIDERED		
/Andrew Freistein/ (08/01/2006)				08/01/2006		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						